Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab Extension in Ovarian Cancer
NCT01018563Phase 2Terminated
- Sponsor
- Morphotek
- Start
- Jan 2010
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of farletuzumab in epithelial ovarian cancer (EOC), sponsored by Morphotek. Started Jan 2010; status: terminated.
02
Drugs
farletuzumab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT01018563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01018563.